In the world of oncology, HER2 (human epidermal growth factor receptor 2) used to represent a simple boundary—positive meant eligibility for treatment; negative meant no access to targeted therapy.. However, with the advent of antibody-drug conjugates (ADCs), this boundary has begun to blur. This article published in Gynecologic Oncology illustrates that:HER2 is no longer a … Read more
On November 17, 2025, the drug clinical trial registration and information disclosure platform showed that AstraZeneca registered the B7-H4 ADC Puxitatug Samrotecan (P-Sam, AZD8205) in a single-agent controlled physician’s choice chemotherapy treatment for patients with advanced/metastatic endometrial cancer (EC) that selectively expresses B7-H4 (≥25% tumor cell expression) and has progressed during or after platinum-based chemotherapy … Read more
Overview The POLE gene belongs to the DNA polymerase B family and is a catalytic subunit of DNA polymerase ε, possessing 5’→3’ DNA polymerase activity and 3’→5’ exonuclease activity, which play a crucial role in DNA replication and proofreading. Mutations in the exonuclease domain of this gene, which includes exons 9 to 14, can lead … Read more